← Back to patent-cliff list
Onvapegleukin alfa
Tier C — Watch / tradeOnvapegleukin alfa
Ascendis Pharma A/S
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：IL2RB, IL-2RG
Indications (approved)：Non-small cell lung cancer, Ovarian cancer, Solid tumour, Head and neck cancer
Regional status
US
Phase II
2022-01-11
EU
Phase II
2022-01-11
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Onvapegleukin alfa?
Approved indications include: Non-small cell lung cancer, Ovarian cancer, Solid tumour, Head and neck cancer.
When does the Onvapegleukin alfa patent expire?
No public expiry year is available for Onvapegleukin alfa yet; this page updates once verified.
How do I get a quote for Onvapegleukin alfa intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21